Received: 31 March 2022
Accepted: 16 November 2022
First Online: 13 December 2022
: Not applicable.
: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
: YC declares no competing interest. ACSL declares consulting/advisory relationship with Merck; research funding from OBI Pharma, Seattle Genetics, and Novartis. CLV declares consulting/advisory relationship and honoraria with Veru, Biotheranostics, and Novartis. MTN declares no competing interest. GW declares research funding from Eisai, Daiichi Sankyo Inc, Immunomedics Inc, Genentech Inc, Pfizer Inc, Pharmacyclics LLC, and Eli Lilly and Company.